SELECTIVE GROWTH INHIBITION AND INDUCTION OF APOPTOSIS IN TUMOR CELLS

Invention Summary

This technology involves novel compounds that selectively inhibit COPZ1, leading to the disruption of the Golgi complex and ER in COPZ2-deficient tumor cells, thus inducing apoptosis. The compounds have been tested and shown to be effective in pancreatic ductal adenocarcinoma (PDAC), breast, and melanoma cells, selectively killing tumor cells while sparing normal cells.

image of tumor cells |NDSU Research Foundation

Benefits

  • Selective Targeting: the compounds selectively inhibit COPZ1, inducing apoptosis in tumor cells without affecting healthy cells
  • Reduced Side Effects: targeted action minimizes damage to healthy cells, potentially reducing side effects compared to conventional therapies
  • Broad Application: effective against various cancers, including pancreatic, breast, and melanoma cells
  • Reduced Usage Rates-higher efficiency allows for lower quantities of fertilizers to be used, reducing costs and environmental impact

Applications

  • Cancer Treatment: particularly effective for cancers with downregulated COPZ2 expressions, such as pancreatic ductal adenocarcinoma, breast cancer, and melanoma
  • Combination Therapy: can be used in conjunction with other anti-tumor agents for enhanced therapeutic effects

Patent

This technology has a U.S. Patent Pending and is available for licensing/partnering opportunities.

Contact

NDSU Research Foundation
info(at)ndsurf(dot)org
(701) 231-8173

NDSURF Tech Key

RFT, 703, RFT703

Inquire about this technology >